Stimuliver Announces Their Scientific Advisory Board
Stimuliver announces that a prestigious group of scientific and clinical thought leaders in the field of regenerative medicine to join the scientific advisory board
The board will guide the development of Stimuliver’s first in class vascularised and immunomodulatory liver implant to treat failing liver function in humans
Copenhagen, Denmark, 2023 – Stimuliver ApS, an emerging biotech company developing a first-in-class tissue implant to treat acute and chronic liver diseases, today announces the composition of their scientific advisory board.
Stimuliver has recruited key players in the field of human regenerative medicine. This includes Prof. Fiona Watt, former director of the Centre for Stem Cells and Regenerative Medicine at King’s College London; Prof. Linda Griffith, Professor of Biological Engineering and Mechanical Engineering at Massachusetts Institute of Technology; Prof. Giovanna Lombardi, Professor of Human Transplant Immunology at King’s College London; and Dr Petter Björquist, serial entrepreneur and CEO of Verigraft. Technology development will be supported by a cutting - edge clinical team, which includes, Prof. Jonathan Fallowfield, NHS Consultant Hepatologist and Professor of Translational Liver Research at the University of Edinburgh, and Mr Ian Currie, a Consultant Surgeon in Transplantation and General Surgery and Honorary Senior Lecturer at the University of Edinburgh.
Stimuliver was founded in Denmark by David Hay and Dagmara Szkolnicka and is a spinout from the University of Edinburgh. We have developed revolutionary proof-of-concept data which demonstrates that human liver tissue can be administered under the skin, providing long-term host liver support in rodents, and favourably modulates the immune system. For chronic liver disease patients, there are benefits of implanting cells subcutaneously, as the liver and abdominal cavity are highly inflamed in these patients, making it a hostile environment to deploy liver cell therapies.
The scalable liver implant technology developed at Stimuliver uses pluripotent stem cells and is not dependent on donor organ availability. This may in the future provide a treatment which is available without waiting time and has the potential to reverse liver disease and prevent hospitalizations.
Stimuliver is incubated at the BioInnovation Institute in Copenhagen.
David Hay, co-founder and CEO said: “We are delighted to be working with such a talented and well respected scientific advisory board. The world leading interdisciplinary expertise of the team is key to translating our unique approach to treat human liver disease to the clinic”
For more information please contact:
Stimuliver
David Hay, CEO
dave@stimuliver.bio
NOTES TO EDITORS
About Stimuliver
Stimuliver is a Danish biotech company with technology from the University of Edinburgh, established to develop a scalable, safe and effective treatment for diseases affecting the liver. The company’s first-in-class, vascularised and immunomodulatory liver tissue implant, aims to treat both acute and chronic liver diseases for which there are limited, and no treatment options currently available. www.stimuliver.bio